PLOS ONE 润色咨询

PLoS One

出版年份：2006 年文章数：239709 投稿命中率： 开通期刊会员，数据随心看

出版周期：Irregular 自引率：6.0% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2022-12-28 ms5000001749363535 来自江苏省

    投稿命中率:95.0
    经验分享：挺容易的

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2023-02-02 ms1000001611299935 来自广东省

    审稿速度:2.0 | 投稿命中率:5.0
    偏重的研究方向：基础医学
    经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand.

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2022-01-08 男护硕士在读

    偏重的研究方向：临床医学
    经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2023-02-17 ms7000001025891884 来自河南省

    请问这个杂志接收综述吗

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2023-02-22 124187b7m16(暂无昵称) 来自河北省

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享：挺好

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2022-05-02 ms2000001344149627

    偏重的研究方向：人工智能;已录用
    经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。

    6

    展开6条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2023-03-03 oxysingin 来自四川省

    审稿速度:4.0 | 投稿命中率:50.0
    偏重的研究方向：综合
    经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2022-05-05 猫星云

    小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张

    7

    展开7条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2022-11-29 ms954663428435720 来自江苏省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向：糖尿病创面
    经验分享：2022.8.29投稿
    大修
    给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的
    2022.11.21接收
    这里先发了预接收信，给了一天时间改格式啥的
    2022.11.29付版面费1805$
    总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的

    6

    展开6条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2107892, encodeId=ee3e210e8927a, content=投稿命中率:95.0<br>经验分享：挺容易的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c8463060, createdName=ms5000001749363535, createdTime=Wed Dec 28 20:17:44 CST 2022, time=2022-12-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112676, encodeId=6c8221126e6fa, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：基础医学<br>经验分享：自认倒霉了遇到韩国人做我的学术编辑，这篇文章感觉要黄了，这个学术编辑另附加了一个回复As academic editor of your manuscript, I have to mention the followings: 1. The decoction is crude extracts-based and therefore, each compound should be explained in separate Tables with appropriate references. 2. The Plos one persues the original and mechanism certainty studies. In this meaning, we can recommend your revision to submit to more specialized jornals such as ethnopharmacology or ethnomedicine, as you agree with. Therefore, your revision is not guaranted to accept, as you would understand. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e925457326, createdName=ms1000001611299935, createdTime=Thu Feb 02 03:15:42 CST 2023, time=2023-02-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1182097, encodeId=f68a118209e9b, content=偏重的研究方向：临床医学<br>经验分享：11.5投的一篇meta分析，现在1.8还在with Editor,发了三次催稿，回复都说已经在催了。但是一点状态栏一直没变，也不知道在干啥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b995273428, createdName=男护硕士在读, createdTime=Sat Jan 08 08:28:51 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115078, encodeId=3fe221150e8ef, content=请问这个杂志接收综述吗<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1a18229808, createdName=ms7000001025891884, createdTime=Fri Feb 17 12:12:54 CST 2023, time=2023-02-17, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2115834, encodeId=dd1521158344a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：挺好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f3f82460729, createdName=124187b7m16(暂无昵称), createdTime=Wed Feb 22 02:16:17 CST 2023, time=2023-02-22, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1216448, encodeId=925b1216448c0, content=偏重的研究方向：人工智能;已录用<br>经验分享：本人在4月11号收到正式录用通知，但是现在还没有看到线上出版的消息，请问大家从录用到出版需要多长时间呀，出版之后还会不会给发邮件通知呢？非常感谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0f5707233, createdName=ms2000001344149627, createdTime=Mon May 02 22:13:18 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117310, encodeId=c32b211e31044, content=审稿速度:4.0 | 投稿命中率:50.0<br>偏重的研究方向：综合<br>经验分享：投稿四个月under review两个半月发邮件说编辑处理不了，要重新找编辑…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dbd5432406, createdName=oxysingin, createdTime=Fri Mar 03 07:34:57 CST 2023, time=2023-03-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1217208, encodeId=3e5d121e208d3, content=小修后四天就直接 decision in process ，都不用送二次外审吗？好紧张 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8db61976017, createdName=猫星云, createdTime=Thu May 05 22:48:14 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103271, encodeId=22e421032e121, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：糖尿病创面<br>经验分享：2022.8.29投稿<br>大修<br>给了一个半月左右，因为忙着毕业论文就在截止时间最后一天返修的<br>2022.11.21接收<br>这里先发了预接收信，给了一天时间改格式啥的<br>2022.11.29付版面费1805$<br>总体感觉很nice，因为这是综合期刊，所以邀请的审稿人稍微有些偏了，但是在返修中我们坚持了自己的想法最后很顺利的接收了~还蛮给人信心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 13:59:06 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2123647, encodeId=c1ec212364e7c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b628619682, createdName=ms4000000517799600, createdTime=Tue Apr 04 11:49:54 CST 2023, time=2023-04-04, status=1, ipAttribution=陕西省)]
    2023-04-04 ms4000000517799600 来自陕西省

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享：这个期刊还是比较看重质量的，需要的可以加**ygbpfdr3037768427，互(ke)相(yi)交(an)流(pai)

    1

    展开1条回复
共500条页码: 7/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分